Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): a Randomized, Double-Blind, Placebo-Controlled Trial

By sjmartinez • February 20, 2025

Gathe JC, Dejesus E, Ramgopal MN, Rolle CP, Yang OO, Sanchez WE, Lalezari JP, Krishen A, Sacha JB, Hansen SG, Meidling J. Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): a Randomized, Double-Blind, Placebo-Controlled Trial. J Acquir Immune Defic Syndr. 2025 Feb 20. doi: 10.1097/QAI.0000000000003648. Epub ahead of print. PMID: 39972543.

Tags: Infectious Diseases, Publications

Climate Change and Coccidioidomycosis

Lee PS, Swain DL, Johnson R. Climate Change and Coccidioidomycosis. JAMA. 2025 Feb 20. doi: 10.1001/jama.2024.27274. Epub ahead of print. PMID: 39976999.

Leptospirosis-Improving Healthcare Outcomes for a Neglected Tropical Disease

Muñoz-Zanzi C, Dreyfus A, Limothai U, Foley W, Srisawat N, Picardeau M, Haake DA. Leptospirosis-Improving Healthcare Outcomes for a Neglected Tropical Disease. Open Forum Infect[...]

Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial

Luetkemeyer AF, Chew KW, Lacey S, Hughes MD, Harrison LJ, Daar ES, Eron J, Fletcher CV, Greninger AL, Hessinger D, Li JZ, Mailhot D, Wohl[...]